COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Injection of Bromelain and Acetylcysteine in Combination Into Recurrent Mucinous Tumour or Pseudomyxoma Peritonei

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03976973
Recruitment Status : Not yet recruiting
First Posted : June 6, 2019
Last Update Posted : March 9, 2020
Mercy Medical Center
Wake Forest University Health Sciences
St George Hospital, Australia
Memorial Sloan Kettering Cancer Center
Catharina Ziekenhuis Eindhoven
Hospices Civils de Lyon
Information provided by (Responsible Party):
David Morris, Mucpharm Pty Ltd

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : November 2021